Related Experiment Videos
Hypertension in end-stage renal disease patients
1Department of Internal Medicine (Nephrology), Univeristy of New Mexico, Albuquerque 87131-5271, USA. pzag@unm.edu
Insights
Hypertension is common in end-stage renal disease (ESRD) and contributes to cardiovascular disease. Due to limited clinical trials, follow National Kidney Foundation guidelines for treatment strategies.
Area of Science:
- Nephrology
- Cardiology
- Hypertension Research
Background:
- High prevalence of hypertension in end-stage renal disease (ESRD) patients.
- Hypertension is a significant risk factor for cardiovascular disease (CVD) in ESRD.
- Limited prospective, randomized clinical trials exist for hypertension management in ESRD.
Purpose of the Study:
- To address the challenges in defining optimal hypertension treatment strategies for ESRD patients.
- To provide guidance on managing hypertension in the context of ESRD and high cardiovascular risk.
Main Methods:
- Review of existing literature and clinical trial data.
- Analysis of current understanding of hypertension's role in ESRD-related CVD.
- Consultation of established clinical practice guidelines.
Main Results:
- Hypertension is a critical issue in ESRD, strongly linked to cardiovascular complications.
- Lack of robust clinical trial evidence complicates definitive treatment recommendations.
- Existing guidelines offer a framework for current management approaches.
Conclusions:
- Current evidence necessitates reliance on established guidelines for hypertension management in ESRD.
- The National Kidney Foundation's Cardiovascular Disease Task Force guidelines are recommended for clinical practice.
- Further research is needed to refine treatment strategies through prospective trials.
Abstract:
The prevalence of hypertension is extremely high in end-stage renal disease, and is a probable contributor to the epidemic of cardiovascular disease in end-stage renal disease. However, the paucity of prospective, randomized clinical trials makes it difficult to precisely define treatment strategies. Therefore, at present time the guidelines developed by the National Kidney Foundation's Cardiovascular Disease Task Force should be followed.